Abstract 582P
Background
Current colorectal cancer (CRC) screening assays decrease CRC-related incidence and mortality. However, effectiveness of screening programs is limited by the very low adherence of the population to screening recommendations. Development of less invasive, more accessible, and more convenient tests is an unmet clinical need.
Methods
A circulating tumor (ct)DNA blood-based assay that integrates genomics, epigenomics and fragmentomics was tested in blood samples from two cohorts: (1) consecutive FIT-positive individuals from the CRC Barcelona stool-based screening program; (2) patients diagnosed with CRC. Colonoscopy was performed in all individuals. Primary endpoint was to establish the accuracy of the assay to detect CRC and advanced adenomas (AA) compared to colonoscopy. A secondary exploratory endpoint analyzed the accuracy of a refined version of the assay (including protein and updating bioinformatic thresholding) to detect AA in a cohort of random FIT-positive individuals from the CRC screening program.
Results
A total of 623 blood samples were analyzed in the primary analysis. Sensitivity and specificity of the assay to detect CRC was 93% and 90%, respectively. The sensitivity of CRC detection was high in all TNM stages (84% stage I, 94% stage II, 96% stage III, 100% stage IV). The test detected advanced neoplasms (AA or serrated lesion or CRC) with a sensitivity of 85% and a specificity of 90%. Sensitivity to detect AA was 23% when using a refined version of the test, with a specificity of 86%.
Conclusions
A blood-based multimodal ctDNA assay detected advanced neoplasms with high accuracy. This non-invasive, accessible, and convenient test is key to increase the population compliance to screening recommendations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital del Mar, Barcelona.
Funding
Has not received any funding.
Disclosure
J. Vidal Barrull: Financial Interests, Personal, Invited Speaker: Merck, Pierre Fabre, Amgen; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb. V.M. Raymond: Financial Interests, Personal, Full or part-time Employment: Guardant Healh. I. Faull: Financial Interests, Personal, Full or part-time Employment: Guardant Healh. B. Bellosillo Paricio: Non-Financial Interests, Personal, Funding: Thermo Fisher; Financial Interests, Personal, Funding: Roche Diagnostics, Roche Pharma, AstraZeneca; Financial Interests, Personal, Invited Speaker: Thermo Fisher, Qiagen, Merck; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca. C. Montagut Viladot: Non-Financial Interests, Institutional, Funding: Merck; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Invited Speaker: Guardant Health, Amgen, Lilly, Sanofi, Biocartis. All other authors have declared no conflicts of interest.
Resources from the same session
612P - Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Presenter: fuxiang zhou
Session: Poster session 10
613P - Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster session 10
614P - Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Josep Tabernero
Session: Poster session 10
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10
618P - Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Presenter: Tae Won Kim
Session: Poster session 10
619P - Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Presenter: Guy Ungerechts
Session: Poster session 10
620P - A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Presenter: Giulia Martini
Session: Poster session 10
621P - The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Presenter: Alexej Ballhausen
Session: Poster session 10